HIV Prevention Drug Access at Risk Due to US Aid Cuts
· news
Cutting Off Progress in HIV Prevention
As experts gathered at the 2026 Aids Conference in Rio de Janeiro, a stark reality emerged: despite groundbreaking innovations in HIV prevention, US foreign aid cuts are blocking access to lifesaving medications for those who need them most. The World Health Organization’s recommendation last year to prioritize expanded access to lenacapavir, an injectable version of PrEP, has been met with bureaucratic barriers and funding constraints.
The WHO’s push for widespread availability of lenacapavir is both a humanitarian imperative and a sound investment in public health. This medication has the potential to prevent 41% of new HIV infections in South Africa, Zimbabwe, and western Kenya, areas where access to traditional PrEP options is severely limited due to poverty, stigma, or geographical isolation. Lenacapavir’s injectable form requires only two annual injections, making it a game-changer for populations facing significant barriers to healthcare.
The timing of the WHO’s recommendation coincided with the Trump administration’s dismantling of USAID, which provided 73% of donor-funded resources for HIV prevention globally. The resulting funding cuts have crippled organizations’ ability to deliver new prevention technologies and engage people in care. “We have major achievements in prevention,” noted Beatriz Grinsztejn, president of the International Aids Society, “but we’re facing significant funding cuts that are affecting deeply the delivery not only of these new prevention technologies but also decreasing the number of people engaged in care.”
Funding cuts extend beyond medication availability to outreach services. Peer outreach workers, crucial for reaching people who inject drugs and building trust with them, have been disproportionately affected by budget constraints. Organizations are forced to shut down locations, including mobile ones, leaving clients at risk of HIV without a reliable point of contact.
This crisis raises questions about our collective commitment to eliminating AIDS as a public health threat by 2030, a goal set out by UNAIDS. “It’s really hard that we’ll get to the targets given the current scenario,” Grinsztejn candidly admitted. The future of HIV prevention hangs in the balance, and it is imperative that policymakers recognize the urgent need for sustained investment in these lifesaving technologies.
The implications of this crisis extend beyond public health. They speak to a broader failure of global leadership and the prioritization of narrow interests over human lives. Policymakers must prioritize access over profits and solidarity over borders to ensure the success of HIV prevention programs. The clock is ticking, and it’s time for action.
Reader Views
- CMColumnist M. Reid · opinion columnist
The US aid cuts are less about fiscal responsibility and more about ideological disdain for global health initiatives. But what gets lost in the policy debates is that these medications aren't just a handout to developing countries – they're a sound investment in public health infrastructure. By prioritizing lenacapavir, we're not only preventing HIV infections but also creating a sustainable model for disease prevention and management that can be replicated elsewhere. The real tragedy here isn't the funding cuts themselves, but the bureaucratic inertia that's stymied efforts to adapt to changing health landscapes.
- RJReporter J. Avery · staff reporter
The US aid cuts are crippling efforts to prevent HIV in Africa, where lenacapavir's injectable form is proving particularly effective. But what's often overlooked is that these medication restrictions also hurt American interests – by undermining global public health and emboldening anti-American sentiment among local populations. We've seen this movie before: the Reagan-era's AIDS denialism created a generation of lost lives, and now we're repeating history with short-sighted foreign policy decisions. It's time to recognize that investing in global HIV prevention is not only humanitarian, but also smart diplomacy.
- EKEditor K. Wells · editor
It's telling that as the HIV epidemic continues to ravage vulnerable communities abroad, US policymakers are more focused on slashing foreign aid than investing in lifesaving interventions. But what gets lost in these grand debates is the human toll: people living with HIV or at risk of contracting it face a stark choice between survival and bureaucratic red tape. The WHO's push for lenacapavir access is critical not just because it prevents infections, but also because it empowers communities to take ownership of their health – something that funding cuts recklessly undermine.